SANUWAVE Health is a commercial wound-care device company whose second-quarter print splits the franchise in two. Recurring applicator demand set another record even as new UltraMIST consoles stopped selling into a customer base that is closing clinics after Medicare skin-substitute clawbacks. That split, not the modest revenue dip, is the investment debate. The equity now trades as if the placement engine is permanently broken, while the consumable engine is still compounding. Management also pulled full-year revenue guidance after a proposed physician-office rate cut on the treatment code that pays for UltraMIST.
Applicator revenue rose to $7.3 million. That gain is the cleanest read on whether UltraMIST is still being used, and the print says it is. System shipments fell to 82 units from the year-ago 116. Used consoles from shuttered wound clinics absorbed an estimated forty to sixty placements that never hit the company's invoice. The installed base still edged higher because someone is treating patients. They are just not always buying the generator from SANUWAVE.
The next several quarters resolve whether applicator compounding survives a reimbursement reset. The proposed physician-office rate for the UltraMIST treatment code falls toward $317. That is a cut from the current average near four hundred. Hospital outpatient rates are proposed higher by fourteen percent. Cash at mid-year sat near $9.4 million against a term loan that is already amortizing. Does utilization keep paying the debt if office economics compress, or does the used-device overhang plus a rate cut freeze placements for good?